Xinfang Hou
Zhengzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial.
Journal: Nature communications
Published: November 17, 2025
Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer.
Journal: British journal of cancer
Published: April 23, 2025
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.
Journal: Signal transduction and targeted therapy
Published: January 18, 2025
A real-world study: third-line treatment options for metastatic colorectal cancer.
Journal: Frontiers in oncology
Published: August 14, 2024
Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study.
Journal: EClinicalMedicine
Published: January 10, 2024
Knockdown of kinesin family member 2C restricts cell proliferation and induces cell cycle arrest in gastric cancer.
Journal: Histology and histopathology
Published: November 30, 2022
Identification of a potential competing endogenous RNA (ceRNA) network in gastric adenocarcinoma.
Journal: Journal of gastrointestinal oncology
Published: October 28, 2022
Long noncoding RNA ZEB1-AS1 attenuates ferroptosis of gastric cancer cells through modulating miR-429/BGN axis.
Journal: Journal of biochemical and molecular toxicology
Published: October 10, 2022
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.
Journal: BMJ (Clinical research ed.)
Published: April 20, 2022
LncRNA MCF2L-AS1 aggravates proliferation, invasion and glycolysis of colorectal cancer cells via the crosstalk with miR-874-3p/FOXM1 signaling axis.
Journal: Carcinogenesis
Published: June 09, 2020
MiR-645 promotes invasiveness, metastasis and tumor growth in colorectal cancer by targeting EFNA5.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: October 28, 2019
Showing 1-12 of 12
Last Updated: 09/26/2026